drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR T cells)
drug_description
Patient-derived T cells genetically engineered to express a chimeric antigen receptor targeting BCMA (TNFRSF17); administered intravenously at 2–4 × 10^6 BCMA CAR+ T cells/kg to eliminate residual multiple myeloma via CAR-mediated T-cell cytotoxicity and cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting BCMA; upon binding BCMA on myeloma/plasma cells, the CAR activates the T cells to deliver targeted cytotoxicity and cytokine release, killing BCMA-positive malignant cells and clearing residual disease.
drug_name
Autologous anti-BCMA CAR-T cells
nct_id_drug_ref
NCT05846737